Recombinant Human Anti-CD44 x Human Anti-CR3 Bispecific Antibody (scFv-CH1/CL) (BSCC-H295)

Recombinant Anti-CD44 x Anti-CR3 Bispecific Antibody (scFv-CH1/CL) is designed to be expressed as two chains. One scFv from an anti-CD44 antibody variable domain is fused to CH1 and the other scFv from an anti-CR3 antibody variable domain fused to CL, or vice versa. And the CH1 and CL domains are linked covalently via a natural disulfide bond. This BsAb can recruit macrophages to tumor cells. It is designed for the research of Glioblastoma; Squamous cancer therapy.

Datasheet INQUIRY

Specifications

Targets

CD44 & CR3

Type

scFv-based Bispecific Fragments

Species Reactivity

Human

Application

FuncS; Promising therapeutic agent

Related Disease

Glioblastoma; Squamous cancer

Targets

Target 1

CD44

Gene ID

960

UniProt ID

P16070

Alternative Names

CD44; CD44 antigen; ECMRIII; Extracellular matrix receptor III; HCAM; Homing cell adhesion molecule; Pgp-1; phagocytic glycoprotein-1; HUTCH-1; Ly-24; Pgp-1; HERMES; AU023126; AW121933; AW146109

Target 2

CR3

Gene ID

719

UniProt ID

Q16581

Alternative Names

C3AR1; complement C3a receptor 1; AZ3B; C3AR; HNFAG09; CR3; Complement receptor type 3; CD11b/CD18; Mac-1; Macrophage antigen 1; αmβ2

Our products and services are for research use only, and not for use in diagnostic or therapeutic procedures.

Online Inquiry

Customer Reviews and Q&As

There are currently no customer reviews or questions for Recombinant Human Anti-CD44 x Human Anti-CR3 Bispecific Antibody (scFv-CH1/CL) (BSCC-H295). Click the button below to contact us or submit your feedback about this product.

Recombinant Human Anti-CD44 x Human Anti-CR3 Bispecific Antibody (scFv-CH1/CL) (CAT#: BSCC-H295)

Specifications

Targets

Customer Reviews and Q&As